Bicara Therapeutics CEO Sold Over 8,000 Company Shares. Is the Stock a Sell or Buy?
This Boston biotech focused on bifunctional cancer therapies reported a notable insider sale amid strong one-year stock gains.
Source: www.fool.com
This Boston biotech focused on bifunctional cancer therapies reported a notable insider sale amid strong one-year stock gains.